Revolution of Alzheimer precision neurology. Passageway of systems biology and neurophysiology

01 Pubblicazione su rivista
Hampel Harald, Toschi Nicola, Babiloni Claudio, Baldacci Filippo, Black Keith L, Bokde Arun L W, Bun René S, Cacciola Francesco, Cavedo Enrica, Chiesa Patrizia A, Colliot Olivier, Coman Cristina-Maria, Dubois Bruno, Duggento Andrea, Durrleman Stanley, Ferretti Maria-Teresa, George Nathalie, Genthon Remy, Habert Marie-Odile, Herholz Karl, Koronyo Yosef, Koronyo-Hamaoui Maya, Lamari Foudil, Langevin Todd, Lehéricy Stéphane, Lorenceau Jean, Neri Christian, Nisticò Robert, Nyasse-Messene Francis, Ritchie Craig, Rossi Simone, Santarnecchi Emiliano, Sporns Olaf, Verdooner Steven R, Vergallo Andrea, Villain Nicolas, Younesi Erfan, Garaci Francesco, Lista Simone
ISSN: 1387-2877

The Precision Neurology development process implements systems theory with system biology and neurophysiology in a parallel, bidirectional research path: a combined hypothesis-driven investigation of systems dysfunction within distinct molecular, cellular, and large-scale neural network systems in both animal models as well as through tests for the usefulness of these candidate dynamic systems biomarkers in different diseases and subgroups at different stages of pathophysiological progression. This translational research path is paralleled by an "omics"-based, hypothesis-free, exploratory research pathway, which will collect multimodal data from progressing asymptomatic, preclinical, and clinical neurodegenerative disease (ND) populations, within the wide continuous biological and clinical spectrum of ND, applying high-throughput and high-content technologies combined with powerful computational and statistical modeling tools, aimed at identifying novel dysfunctional systems and predictive marker signatures associated with ND. The goals are to identify common biological denominators or differentiating classifiers across the continuum of ND during detectable stages of pathophysiological progression, characterize systems-based intermediate endophenotypes, validate multi-modal novel diagnostic systems biomarkers, and advance clinical intervention trial designs by utilizing systems-based intermediate endophenotypes and candidate surrogate markers. Achieving these goals is key to the ultimate development of early and effective individualized treatment of ND, such as Alzheimer's disease. The Alzheimer Precision Medicine Initiative (APMI) and cohort program (APMI-CP), as well as the Paris based core of the Sorbonne University Clinical Research Group "Alzheimer Precision Medicine" (GRC-APM) were recently launched to facilitate the passageway from conventional clinical diagnostic and drug development toward breakthrough innovation based on the investigation of the comprehensive biological nature of aging individuals. The APMI movement is gaining momentum to systematically apply both systems neurophysiology and systems biology in exploratory translational neuroscience research on ND.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma